Recherche
-
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue -
Pharmacovigilance - The next chapter
(Thérapie. vol. 74, n° 6, pp. 557-567, 2019-12)Article de revue -
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
(British Journal of Clinical Pharmacology. vol. 85, n° 2, pp. 432-441, 2019)Article de revue -
Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study
(British Journal of Clinical Pharmacology. vol. 85, n° 11, pp. 2524-2539, 2019-11)Article de revueLibre accès -
Pharmacoepidemiology of non-steroidal anti-inflammatory drugs
(Therapie. vol. 74, n° 2, pp. 271-277, 2019-04)Article de revue -
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
(Clinical Pharmacology and Therapeutics. vol. 105, n° 6, pp. 1439-1455, 2019)Article de revue